Pharma giant Mylan NV today said its subsidiary Mylan Pharmaceuticals
has launched Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets) in the
Sovaldi is used for the treatment of chronic hepatitis-C infection as a component of a combination anti-viral treatment.
It is estimated that around 12 million people are chronically infected with hepatitis-C in India, Mylan said in a release.
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.
Read more at:
Labels: India, Mylan, Sovaldi